Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
(Reuters) - European shares jumped on Wednesday after Ukraine accepted the U.S.' proposal for a 30-day ceasefire with Russia, ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Clinical Trials Arena on MSN1d
Enrolment concludes in Zealand’s Phase IIb obesity therapy trialZealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback